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Edited by Ga´spa´r Je´kelyAbstract The matrilins form a four-member family of modular,
multisubunit matrix proteins, which are expressed in cartilage
but also in many other forms of extracellular matrix. They par-
ticipate in the formation of ﬁbrillar or ﬁlamentous structures and
are often associated with collagens. It appears that they mediate
interactions between collagen-containing ﬁbrils and other matrix
constituents, such as aggrecan. This adaptor function may be
modulated by physiological proteolysis that causes the loss of
single subunits and thereby a decrease in binding avidity. At-
tempts to study matrilin function by gene inactivation in mouse
have been frustrating and so far not yielded pronounced pheno-
types, presumably because of the extensive redundancy within
the family allowing compensation by one family member for an-
other. However, mutations in matrilin-3 in humans cause diﬀer-
ent forms of chondrodysplasias and perhaps also hand
osteoarthritis. As loss of matrilin-3 is not critical in mouse, these
phenotypes are likely to be caused by dominant negative eﬀects.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The matrilins are a family of non-collagenous extracellular
matrix proteins that form a subbranch of the superfamily of
proteins containing von Willebrand factor A (VWA) domains
(for review, see [1]). VWA domains are present in a large num-
ber of extracellular and intracellular proteins and often partic-
ipate in protein–protein interactions leading to the formation
of multiprotein complexes.2. The family members and their structure
The matrilin family consists of four members with a closely
similar domain structure (Fig. 1). Two VWA domains are con-
nected by a varying number of epidermal growth factorAbbreviations: COMP, cartilage oligomeric matrix protein; EGF,
epidermal growth factor; p.c., post coitum; VWA, von Willebrand
factor A
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helical coiled-coil domain which allows the oligomerisation
of the single subunits in a bouquet-like fashion. Only matri-
lin-3 lacks the second VWA domain and here the EGF-like
domains are directly connected to the coiled-coil domain. In
addition, matrilin-2 and -3 contain a stretch of amino acid res-
idues at the N-terminus with a high frequency of positively
charged side chains. Uniquely, matrilin-2 contains a module
between the second VWA domain and the oligomerisation
domain that has no homology to any other known protein
sequence.
VWA domains consist of about 200 amino acid residues in a
classical Rossman fold with a central b-sheet surrounded by a-
helices. A MIDAS (metal ion dependent adhesion site) motif
(DXSXSXnTXnD), which may be involved in ligand binding,
is perfectly conserved in nearly all matrilin VWA domains. The
VWA domains of matrilins represent an own subgroup of the
VWA domains of extracellular matrix proteins (http://
www.ncbi.nlm.nih.gov/Structure/cdd/cdd.shtml) [2]. All matri-
lin VWA domains have higher identity to the members of the
subgroup than to any other VWA domain, indicating that they
originate from a common ancestor VWA domain [3]. Phyloge-
netic studies assigned the ﬁrst and the second VWA domains
into two diﬀerent groups, of which each splits into a matri-
lin-1/3 and a matrilin-2/4 subbranch [3]. Among other VWA
domain family members, the VWA domains of diﬀerent colla-
gens, vitrin, a1 integrin, WARP and AMACO have the highest
identity (30%). It is probable that the VWA domains are the
principal interaction modules of matrilins, since matrilin-1 and
-3 splice variants exist in zebraﬁsh that lack all EGF domains
[4].
All other matrilins contain at least one EGF-like domain,
the highest number being in a splice variant of zebraﬁsh matri-
lin-4 where 12 EGF domains are present [4]. EGF domains
contain 40–50 amino acid residues including six conserved
disulphide bonds. The structure shows a two-stranded b-sheet
and often EGF domains are present in multiple copies [5]. A
comparison of the matrilin EGF domains with the key residues
of calcium-binding motifs in calcium binding EGF domains
[5,6] showed no match with the consensus sequence. Neither
was a non-canonical calcium-binding site [7] detected in matri-
lin EGF domains. Database searches show that EGF domains
of scube proteins, ﬁbulins and ﬁbrillins have the highest
homologies to matrilin EGF domains.
The matrilins contain a C-terminal a-helical coiled-coil
domain that allows oligomerisation of the subunits in ablished by Elsevier B.V. All rights reserved.
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heptad repeats (a–g) of amino acid residues that typically have
non-polar amino acids at position a and d. The coiled-coil do-
mains of matrilins contain 4.5 heptad repeats showing the least
perfect match with the consensus sequence for matrilin-3. By
electron microscopy of full-length proteins, it has been shown
that matrilin-1 and -4 form homo-trimers [8,9], whereas
matrilin-2 and -3 form homo-tetramers [10,11] (Fig. 1). The
oligomerisation was also studied by using recombinantly ex-
pressed coiled-coil domains [12]. In contrast, here the coiled-
coil domain of matrilin-2 formed only trimers. It could well
be that the oligomerisation is inﬂuenced by the unique domain
adjacent to the coiled-coil domain of matrilin-2. Hetero-oligo-
meric forms of matrilin-1 and -3 have been isolated from fetal
human and calf cartilage [11,13,14]. There is no conclusive evi-
dence for natural occurrence of other hetero-oligomers, but a
SDS–PAGE band from an extract of newborn mouse epiphy-
seal cartilage was shown by peptide mass ﬁngerprinting to con-
tain both matrilin-1 and -4 (G. Sengle, unpublished results).
The analysis of oligomerisation in mixtures of isolated
coiled-coil domains showed a broad range of interactions
and the only hetero-oligomers not found were those containing
matrilin-2 and -3 or matrilin-3 and -4 [12].
Matrilin-1, which was ﬁrst puriﬁed from bovine cartilage, is
the prototype member of the family and was originally called
‘‘cartilage matrix protein’’ or CMP [15]. It is an abundant
protein in many forms of cartilage. The single subunit has a
molecular weight of 52 000 Da and contains 3.9% carbohy-
drate, probably in the form of N-linked glycans [15]. In elec-
tron microscopy matrilin-1 shows the typical bouquet-like
structure where the single VWA domains of the subunits
are not resolved, indicating an interaction between VWA1
and VWA2 (Fig. 1). The solution structure of the oligomeri-Fig. 1. Domain structure of mouse matrilins. On the left, electron microscopy
below ﬁgure. The electron micrographs were reproduced from [8–11] with psation domain of matrilin-1 has been determined by heteronu-
clear NMR spectroscopy. As predicted, the domain folds into
a parallel, disulﬁde-linked, three-stranded, a-helical coiled-
coil, spanning ﬁve heptad repeats in the amino acid sequence
[16].
Matrilin-2 is the largest matrilin with a calculated molecular
weight of 104 300 Da and also carries N-linked glycans [10].
Similar to matrilin-1, in electron microscopy the two VWA do-
mains appear to bind to each other causing the subunit to form
a loop extending from the central coiled-coil (Fig. 1). Both re-
combinant matrilin-2 and the protein detected by immunoblot
in tissue extracts display an unusual extent of structural heter-
ogeneity, most likely due to proteolytic processing.
Matrilin-3 is the smallest family member and is mostly co-
expressed with matrilin-1 [11,17]. By MALDI-TOF mass spec-
trometry, the molecular weight was determined to 49 300 Da.
This value closely matches the calculated mass, indicating the
lack of glycosylation. Due to the absence of the second
VWA domain, there is no self-interaction in the subunits and
in electron microscopy the tetrameric matrilin-3 appears to
have more extended, ﬂexible arms (Fig. 1).
Matrilin-4 contains in mouse four EGF domains between
the two VWA domains [9,18]. The recombinant protein has
a molecular weight of 72 900 Da indicating 7% posttransla-
tional modiﬁcations. Although matrilin-4 carries two VWA
domains, in electron microscopy these show no obvious inter-
action (Fig. 1). The images show the three C-terminal VWA
domains at the center, presumably held together by the
coiled-coil domain. The subunits extend from this central
structure and end in globular domains representing the N-ter-
minal VWA domain. The structure of matrilin-4 is reminiscent
of that of matrilin-3, except for the latter protein forming
tetramers.after negative staining is shown. For explanation of symbols, see frame
ermission.
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Studies on matrilins have been focussed on cartilage. All
four members of the matrilin family have been shown to
be present in cartilage matrix, even though it is mainly matri-
lin-1 and -3 that are prominent in this tissue. Further, matri-
lin expression is strictly regulated also within cartilage tissue,
both in a temporal and in a spatial manner. Matrilin-1 can
be detected by antibody labelling in myocardium at 9.5 days
post coitum (p.c.) [19]. This expression is, however, transient
and of unknown physiological signiﬁcance. More lasting
expression is seen for both matrilin-1 and -3 in the condens-
ing mesenchyme at day 12.5 p.c. As skeletal development
continues, the expression domains of matrilin-1 and -3 are
similar to that of collagen II, but in late development it be-
comes noticeable that deposition of these matrilins at the
articular surface is not as pronounced as in deeper cartilage
layers [19,20]. In the mouse tibial growth plate matrilin-1 and
-3 proteins are abundant in resting, proliferating and hyper-
trophic cartilage [20], but in situ hybridisation analysis for
matrilin-1 mRNA showed a downregulation concomitant
with the progress of hypertrophy at later stages of chondro-
genesis [21]. As calciﬁcation occurs matrilin-1 and -3 become
incorporated into the calciﬁed cartilage that is gradually re-
placed by proper bone tissue. Continued expression of matri-
lin-1 is seen in tissues that remain cartilaginous during the
whole lifespan, e.g., in costal cartilage and in the nasal sep-
tum, while matrilin-3 expression in these tissues ceases after
birth [20]. It is likely that most matrilin biosynthesis occurs
early in life, but that protein remains because of a slow
turnover.
The expression patterns of matrilin-2 and -4 are much
broader than those of matrilin-1 and -3 and, despite being
present also in cartilage, those proteins are found mainly in
loose connective tissue. The ﬁrst matrilin-2 expression in the
mouse embryo is in heart, just like for matrilin-1, but matri-
lin-2 is expressed later, at day 10.5 p.c., and the expression con-
tinues [20]. Later in development, it is produced by a wide
variety of connective tissue cells, but also by smooth muscle
cells and some epithelia [10]. Matrilin-2 protein is deposited
by these cells into their pericellular matrix. In some cases, it be-
comes associated with basement membranes, even though it is
uncertain if it is an integral basement membrane protein. In
other cases, matrilin-2 is found as a component of a ﬁlamen-
tous network of unknown overall composition [10]. In general,
matrilin-2 has a complementary expression pattern to matrilin-
1 and -3, even though there is some matrilin-2 present also in
cartilage. Matrilin-4 in turn is the most ubiquitous of all matri-
lins and appears to be present, wherever another matrilin is
found [9]. It can be detected by immunohistochemistry in the
ectoplacental cone already at day 7.5 p.c. [9]. The expression
in nervous tissue is more pronounced than for other matrilins,
and indeed the brain appears to be the most abundant tissue
source for matrilin-4.
The tissue distribution of all or some matrilins has also been
determined in man [22], chicken [23,24] and zebraﬁsh [4]. From
the limited data available matrilin expression patterns appear
highly conserved.
The genetic basis for matrilin-1 gene expression has been
studied in some detail in the chicken system. A minimal pro-
moter has been deﬁned that functions both in chondrocytes
and ﬁbroblasts [25]. An enhancer exerts a chondrocyte-speciﬁcstimulation on the promoter activity and a silencer inhibits
activity both in chondrocytes and ﬁbroblasts. The enhancer
is independent of the developmental stage of the chondrocytes,
while promoter upstream control regions appear to restrict the
promoter activity to certain chondrocyte developmental stages
[26]. Transgenic experiments with the chicken matrilin-1 pro-
moter in mouse have indicated that the tissue-speciﬁc control
elements are divided between the promoter upstream and in-
tronic regions in a manner similar to that of the Col11a2 gene
[27].
Matrilins, in particular matrilin-2 and -4, when isolated from
tissues or cell cultures are often degraded and actually seen as a
ladder of bands in SDS–PAGE representing, in addition to the
full-length proteins, fragments lacking the greatest part of one
or more subunits [9,10]. This processing was studied in some
detail for matrilin-4, which when recombinantly expressed in
human embryonic kidney-derived 293 cells is found as a mix-
ture of monomers, dimers and trimers [9]. Analysis of frag-
ments by MALDI-TOF mass spectrometry and Edman
degradation showed that the cleavage occurs at a distinct site
in a short linker region which resides between the C-terminal
VWA domain and the coiled-coil. The processing results in
an almost complete subunit being released from the major part
of the molecule consisting of the coiled-coil together with
remaining subunits. Similar linker regions occur also in the
other matrilins, but it is noteworthy that in matrilin-1, which
is the least sensitive to proteolysis, this linker is the shortest.
At least for matrilin-4 it has been shown that fragments corre-
sponding to those characterised for the recombinant protein
occur also in tissue extracts [9]. It appears that this depolymer-
isation is a physiological process and it may serve the purpose
of decreasing the avidity of matrilins for their ligands and
thereby cause a disassembly of supramolecular structures held
together by matrilins.4. Interactions and potential functions
Matrilin-1 was ﬁrst recognised as a protein tightly bound
to aggrecan and copuriﬁed with aggrecan in a variety of sep-
aration methods [28]. The complexes appear to be formed by
protein–protein interactions occurring along the extended
chrondroitin–sulphate-attachment region of aggrecan. The
bound matrilin-1 molecules with time become covalently
cross-linked to the aggrecan core protein, with at least some
of the crosslinks not being sensitive to reduction [29]. It is
not known if this complex formation is unique for
matrilin-1 and aggrecan or if also other matrilins can bind
to proteoglycans, perhaps to other members of the lectican
family.
An association was also found between matrilin-1 and carti-
lage collagen ﬁbrils and immunolabelling at the electron
microscopy level even indicated a certain periodicity in the
matrilin-1 distribution [30]. Chondrocyte cell culture experi-
ments showed matrilin-1 present in two kinds of pericellular
ﬁlaments, where one type was collagen-dependent, as it re-
quired ascorbate for formation, and the other not [31]. Similar
staining of ﬁlaments in the pericellular matrix of cultured cells
has been seen for each of the other matrilins (Fig. 2) and, in
case of matrilin-2 and -4, not only around chondrocytes, but
also in cultures of other cell types that express these matrilins
[9–11].
Fig. 3. Structure of intact collagen VI from the Swarm rat chondro-
sarcoma as seen by electron microscopy after negative staining. (a)
Collagen VI microﬁbrils with diﬀerent molecules bound close to the N-
terminal parts of the collagen VI tetramers are visible (arrows).
Representative particles exhibiting multidomain structures of diﬀerent
sizes are shown at higher magniﬁcation (insets). Using speciﬁc gold-
labelled antibodies these molecules are identiﬁed as biglycan (b),
decorin (c), matrilin-1 (d), matrilin-3 (e), matrilin-4 (f), and chond-
roadherin (g). Thus, complexes of matrilin-1, -3, or -4 and the leucine-
rich repeat proteoglycans biglycan or decorin, binding close to the
collagen VI N-termini, are identiﬁed. The bars represent 100 nm (a)
and 20 nm ((b)–(g)). Reproduced from [34] with permission.
Fig. 2. Immunoﬂuorescence microscopy of matrilin-3 in the extracel-
lular matrix of primary mouse chondrocytes. Matrilin-3 was detected
with aﬃnity-puriﬁed primary antibodies and a Alexa-Fluor 488-
conjugated secondary antibody. The bar is 50 lm.
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interact with matrilins to form such matrix assemblies. In stud-
ies of matrilin-1, -3, and -4 [32] and matrilin-2 [33] a variety of
collagens were found to bind to matrilins in solid phase assays.
However, some non-collagenous molecules, in particular carti-
lage oligomeric matrix protein (COMP) and decorin, bound to
matrilins with higher aﬃnity [32] and as COMP and decorin
are known to interact with collagens, it may well be that matri-
lins are attached to collagen ﬁbrils as part of a ‘‘sandwich’’
where other components may be the direct and high-aﬃnity
collagen binders. Evidence in this direction comes from studies
where the composition and assembly of molecular complexes
attached to collagen VI-containing microﬁbrils were studied
[34]. With the use of gold-labelled antibodies or matrix pro-
teins as probes, it could be shown that decorin and biglycan at-
tach to VWA domains in the N-terminal region of collagen VI
and that matrilins were in turn bound to these small, leucine-
rich repeat proteoglycans (Fig. 3). At the periphery of these
assemblies, matrilins could be seen to connect the collagen
VI-containing microﬁbrils to aggrecan core proteins or to col-
lagen II-containing ﬁbrils.5. Matrilins in disease and in genetic mouse models
Mutations in matrilin-3 were found to be linked to autoso-
mal dominant forms of multiple epiphyseal dysplasia
(MED), a relatively mild and clinically variable osteochondro-
dysplasia, primarily characterised by delayed and irregular
ossiﬁcation of the epiphyses and early onset osteoarthritis
[35]. The mutations mostly aﬀect residues within the conserved
b strands of the single VWA domain of matrilin-3 [36,37]. In
bilateral hereditary micro-epiphyseal dysplasia (BHMED),
which gives a skeletal phenotype similar to but still distinct
from common MED, a site close to the b-strands in the
VWA domain of matrilin-3 is aﬀected [38]. MED is commonly
caused by autosomal dominant mutations in the genes encod-
ing COMP [39] and the a1, a2, and a3 chains of type IX col-
lagen (COL9A1, COL9A2, and COL9A3) [40–42] and it is ofinterest that mutations in the functionally related protein
matrilin-3 causes similar phenotypes. In addition, in an auto-
somal recessive form of another osteochondrodysplasia,
spondylo-epi-metaphyseal dysplasia (SEMD), that is associ-
ated with vertebral, epiphyseal, and metaphyseal anomalies,
again the matrilin-3 gene is aﬀected [43]. The disease is caused
by a change of a cysteine into a serine in the ﬁrst EGF domain
of matrilin-3, which could lead to a disturbance in the disul-
phide bond formation. In a genomic screen of the Icelandic
population, a mutation in the ﬁrst EGF domain of matrilin-
3 was linked to the occurrence of hand osteoarthritis. Slightly
more than 2% of patients with hand osteoarthritis carry the
mutation [44], but it was also identiﬁed in unrelated controls
[36,44]. In a recent study, the inﬂuence of those MED, SEMD
and hand osteoarthritis mutations on the secretion of matrilin-
3 was studied [45]. Whereas matrilin-3 carrying the hand osteo-
arthritis mutation could be secreted by chondrocytes at a
similar rate as wildtype matrilin-3, the matrilin-3 mutants
causing MED and SMED, respectively, were retained in the
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chondrocyte dysfunction by which MED and SMED pheno-
types could be explained. Similar observations were earlier
made for COMP mutations leading to MED (for review see
[46,47]). In contrast, the mutant matrilin-3 that has been linked
to hand osteoarthritis is synthesised, processed, secreted and
deposited in a way indistinguishable from the wildtype protein,
suggesting, at the most, subtle eﬀects of this mutation on the
structure and function of the protein [45].
Matrilin-1, which has a similar tissue distribution as matri-
lin-3 and is abundant in cartilage, has been excluded as the mu-
tant locus in several heritable chondrodysplasias [48]. In
particular, MED mutations were not found in the four exons
coding for the VWA domains of matrilin-1 in 43 unrelated
MED patients [36]. The linkage of the matrilin-1 locus to
osteoarthritis is controversially discussed. Whereas a linkage
was found in the Dutch population [49], no linkage was seen
among the British [50]. No genetic disorders have been found
involving mutations in matrilin-2 or -4.
Relapsing polychondritis is a rare autoimmune disease of
unknown origin characterised by recurrent episodes of inﬂam-
mation and progressive destruction of cartilaginous tissues
[51]. In such patients autoantibodies against matrilin-1 were
detected [52,53]. An animal model for the disease can be in-
duced by immunizing rats or mice with matrilin-1 [54,55]. In
such experimental relapsing polychondritis, it was shown that
B-cells as well as the complement factor C5 are important for
the induction [55]. In addition to the humoral immune re-
sponse, also macrophages and CD4+ T cells are involved in
the pathogenesis, whereas Il10 has the potential to suppress
the disease [56].
Matrilins may potentially serve as markers for a disturbed
cartilage metabolism in joint disease. It has been reported that
the expression of matrilin-1 is enhanced in knee osteoarthritic
cartilage and knee or hip rheumatoid arthritic cartilage [57]. In
addition, elevated serum levels of matrilin-1 were detected in
patients with active rheumatoid arthritis [58]. Matrilin-1 also
showed an increased expression in specimens from arthritic
condylar cartilage of the temporomandibular joints [59]. Sim-
ilarly, the expression of matrilin-3 has been shown to be in-
creased in knee osteoarthritic cartilage [60].
In the light of the clear role of matrilins in human disease, it
was surprising that all mouse matrilin null mutants generated
so far show no obvious phenotype [61–64]. In one of the matri-
lin-1 knockouts, an abnormal ﬁbril organisation and a slightly
increased diameter of collagen type II ﬁbrils was detected [64],
but no similar ﬁndings were made in an independently per-
formed matrilin-1 gene inactivation [61]. Although the matri-
lin-4 null mutants are not yet available, the lack of obvious
phenotypes in the single knockouts of matrilin-1, -2 and -3
indicates a considerable redundancy within the matrilin family.6. Perspectives
Despite increased information on matrilin interactions the
detailed in vivo functions are still not known. It is clear that
matrilins serve as adaptors in the assembly of supramolecular
structures in the extracellular matrix, but we do not know to
what extent this role is static or dynamic in nature. Matrilins
need to be studied in genetic models, but the redundancy with-
in the family has caused problems in this regard and the threesingle gene inactivations performed so far for matrilin-1, -2
and -3 have not yielded any change in phenotype. These stud-
ies are at present being continued through the establishment of
double knockouts and, in parallel, a knock-down approach is
taken in zebraﬁsh in the hope that compensation is less pro-
nounced in this model organism.
In addition to participating in extracellular matrix assembly
matrilins may participate in cell–matrix interactions. Matrilin-
containing ﬁbrils and ﬁlaments certainly occur close to the cell
surface (Fig. 2), but despite an early report on integrin a1b1
being a matrilin-1 receptor [65], the potential cellular interac-
tions of matrilins have not been systematically studied.
Interaction studies performed with matrilins and other ma-
trix proteins point to the oligomeric structure of the proteins
being important for high-aﬃnity binding. This has made the
mapping of binding sites diﬃcult, but indirect results point to
the VWA domains being most important in mediating inter-
actions with other matrix proteins. It would be of great inter-
est to deﬁne binding sites on matrilin domains by
mutagenesis, but such studies would become easier if the
three-dimensional structure of matrilin domains could be
determined. The degree of identity to VWA domains of
known structure is not high enough to yield reliable struc-
tures of matrilin VWA domains by modelling approaches
and it would therefore not be possible to mutate only sur-
face-exposed residues. Experimental determination of the
three-dimensional structure of at least one matrilin VWA do-
main would overcome this problem.
Such studies would allow not only promote the determina-
tion of matrilin structure and function, but also yield insight
into how mutations in these proteins may cause inherited dis-
ease. Even though intracellular accumulation of misfolded
proteins may be a major contributor to the phenotypes seen
in matrilin-3 dependent osteochondrodysplasias, other muta-
tions causing more discrete changes may cause phenotypes
by other mechanisms.
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